Corbus Pharmaceuticals Announces Abstracts Accepted for Presentation at ASCO 2026 Featuring Updated Clinical Data for CRB-701
Rhea-AI Summary
Corbus Pharmaceuticals (NASDAQ: CRBP) announced that updated Phase 1/2 clinical data for CRB-701, a next-generation Nectin-4 ADC, will be presented at ASCO 2026 May 29–June 2 in Chicago.
Presentations include an oral session for cervical cancer (May 29) and a poster for HNSCC (May 30). Abstracts post on May 21, 2026. Corbus expects to start a registrational study in second-line HNSCC in mid-2026 and to report CRB-701 plus Keytruda combination data in Q4 2026.
AI-generated analysis. Not financial advice.
Positive
- ASCO 2026 presentations scheduled for May 29–30
- Updated Phase 1/2 data includes response durability and HNSCC subgroup analysis
- Company expects to initiate registrational study mid-2026 in second-line HNSCC
- Anticipated CRB-701 + Keytruda data expected Q4 2026 to support registration
Negative
- CRB-701 remains in Phase 1/2 with no completed registrational results yet
- Abstract full data unavailable until ASCO abstracts publish May 21, 2026
News Market Reaction – CRBP
On the day this news was published, CRBP gained 2.77%, reflecting a moderate positive market reaction. Argus tracked a trough of -10.9% from its starting point during tracking. Our momentum scanner triggered 5 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $5M to the company's valuation, bringing the market cap to $185.88M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Pre-news, CRBP was down 3.06% while close peers were mixed: BMEA -7.28%, PYXS +0.59%, EQ +8.04%, FATE -3.57%, KALA -7.45%, suggesting stock-specific factors rather than a clear sector trend.
Previous Clinical trial Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jun 30 | CRB-913 MAD start | Positive | -6.8% | Initiated multiple ascending dose Phase 1 work for obesity drug CRB-913. |
| Mar 28 | CRB-913 first dosing | Positive | -4.7% | First patient dosed in Phase 1 trial of next‑generation CB1 inverse agonist. |
| Feb 14 | CRB-701 Phase 1 data | Positive | -10.2% | ASCO‑GU 2025 Phase 1 results showing encouraging safety and efficacy for CRB-701. |
| Feb 11 | CRB-701 ASCO-GU abstract | Positive | -10.2% | Announcement of updated dose‑escalation data for CRB‑701 at ASCO‑GU 2025. |
| Jan 08 | CRB-701 data notice | Positive | -1.3% | Notification that CRB‑701 Western dose‑escalation data would be presented at ASCO‑GU. |
Clinical-trial announcements have often been followed by negative next-day moves, even when the updates described trial progression or encouraging data.
Over the past year, Corbus has repeatedly highlighted clinical progress across obesity and oncology. For CRB-913, milestones included first patient dosing and initiation of multiple ascending dose work, with development mapped through Q3 2025 and into H2 2026. For CRB-701, the company has advanced a Phase 1 program with Western dose-escalation and dose-optimization data, including ASCO-GU 2025 presentations. Despite generally constructive updates, same-tag clinical news around both CRB-913 and CRB-701 previously corresponded to negative one-day price reactions.
Historical Comparison
Clinical‑trial updates for Corbus have averaged a -6.63% next‑day move, indicating that even constructive data or trial progress has historically been met with cautious trading.
Clinical news shows progression from early Phase 1 CB1 obesity work toward longer dosing and from initial CRB‑701 dose‑escalation into broader Western data and dose optimization.
Regulatory & Risk Context
An effective S-3 shelf filed on 2026-03-11 permits up to $300,000,000 of securities issuances, including equity and debt, via future supplements. A 424B3 filing on 2026-03-25 reflects initial usage of this shelf.
Market Pulse Summary
This announcement highlights further validation of CRB‑701 with oral and poster slots at ASCO 2026, plus clear timelines: a second‑line HNSCC registrational study in mid‑2026 and Keytruda‑combination data in Q4 2026. Historically, Corbus’ clinical updates have often been followed by cautious trading, underscoring execution and data‑quality risk. Alongside this, an effective $300,000,000 shelf registration provides funding flexibility but also raises dilution considerations investors should monitor.
Key Terms
phase 1/2 medical
antibody–drug conjugate medical
nectin-4 medical
head and neck squamous cell carcinoma medical
hnscc medical
cervical cancer medical
registrational study medical
AI-generated analysis. Not financial advice.
NORWOOD, Mass., April 22, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP), a clinical-stage company focused on promising new therapies in oncology and obesity, today announced that updated clinical data from its Phase 1/2 study of CRB-701, a next generation Nectin-4 ADC, in both head and neck squamous cell carcinoma (HNSCC) and cervical cancer will be presented at the upcoming 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, to be held May 29 – June 2 in Chicago, IL.
The data will include clinical response durability as well as HNSCC patient subgroup analysis. Corbus previously presented dose optimization data from the study, including encouraging efficacy and safety findings, at the 2025 European Society for Medical Oncology Congress (ESMO 2025).
Oral Presentation
A phase 1/2 study of the next-generation Nectin-4-targeting antibody–drug conjugate CRB-701 (SYS6002) in patients with recurrent or metastatic cervical cancer - (Tudor-Eliade Ciuleanu, MD, PhD, Arensia Research Clinic; Dominique Berton, MD, Institut de Cancérologie de l'Ouest; et al)
Presenter: Professor Yohann Loriot, Gustave Roussy (Paris)
Session Date and Time: May 29, 4:57 PM CDT
Session Title: Gynecological Cancer
Abstract #: 5508
Poster Presentation:
A phase 1/2 study of the next-generation Nectin-4-targeting antibody–drug conjugate CRB-701 (SYS6002) in patients with recurrent or metastatic head and neck squamous cell carcinoma - (Charlene Mantia, MD, Glenn J Hanna, MD; Dana Farber, et al)
Presenter: Charlene Mantia, MD, Dana Farber Cancer Institute (Boston)
Session Date and Time: May 30, 4:30 PM CDT
Session Title: Head and Neck Cancer
Abstract #: 6062
Poster Board: 519
The abstracts will be available on the ASCO® website on May 21, 2026 at 5:00 p.m. ET.
Corbus expects to initiate a registrational study for CRB-701 in second-line HNSCC in mid-2026.
Corbus also anticipates reporting data with CRB-701 in combination with Keytruda® in first-line HNSCC patients in Q4 2026 to support potential further registration-enabling trials.
About CRB-701
CRB-701 (SYS6002) is a next-generation antibody drug conjugate (ADC) targeting Nectin-4, that contains a site-specific, cleavable linker and a homogenous drug antibody ratio of 2, using MMAE as the payload. Nectin-4 is a clinically validated, tumor-associated antigen in urothelial cancer. The FDA has granted two Fast Track designations to CRB-701 in HNSCC and cervical cancer. CRB-701 is licensed from CSPC Megalith Biopharmaceutical Co. Ltd. China.
About Corbus
Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage company focusing on promising new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing innovative scientific approaches to well-understood biological pathways. Corbus’ pipeline includes CRB-701, a next-generation antibody drug conjugate for the treatment of Nectin-4-expressing tumors, and CRB-913, an orally delivered highly peripherally restricted CB1 inverse agonist for the treatment of obesity. Corbus is headquartered in Norwood, Massachusetts. For more information on Corbus, visit corbuspharma.com. Connect with us on X, LinkedIn and Facebook.
Forward-Looking Statements
This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company’s trial results, product development, clinical and regulatory timelines, including timing for completion of trials and presentation of data, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statement that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management’s current beliefs and assumptions.
These statements may be identified by the use of forward-looking expressions, including, but not limited to, “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “potential,” “predict,” “project,” “should,” “would” and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors on our operations, clinical development plans and timelines, which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company’s filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.
INVESTOR CONTACTS:
Sean Moran
Chief Financial Officer
Corbus Pharmaceuticals
smoran@corbuspharma.com
Dan Ferry
Managing Director
LifeSci Advisors, LLC
daniel@lifesciadvisors.com
MEDIA CONTACT:
Liz Melone
Founder & Principal
Melone Communications, LLC
liz@melonecomm.com
